BCRX FY 2018 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-18.0% YoY

Gross Profit

$20M97.7% margin

Operating Income

-$94M-456.2% margin

Net Income

-$101M-490.3% margin

EPS (Diluted)

$-0.98

Cash Flow

Operating Cash Flow

-$93M

Free Cash Flow

-$93M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$147M

Total Liabilities

$98M

Stockholders' Equity

-$732M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$25M	-18.0%
Gross Profit	$20M	$23M	-14.1%
Operating Income	-$94M	-$57M	-64.1%
Net Income	-$101M	-$66M	-53.9%